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Abstract
Introduction: Pheochromocytomas and paragangliomas are derived from neural crest cells and are localized mainly in adrenal medulla
and sympathetic or parasympathetic ganglia. They can be inherited (25%) and be part of multi-endocrine syndromes such as MEN2
syndrome, von Hippel-Lindau syndrome, pheochromocytoma/paraganglioma syndrome, neurofibromatosis type 1, and Sturge-Weber
syndrome. Clinical presentation can sometimes be atypical and does not always allow proper diagnosis. In such situations, DNA analysis
can be helpful, especially when the pheochromocytoma is the first and only symptom.
Material and methods: We analyzed DNA from 60 patients diagnosed and treated in the Centre of Oncology with a diagnosis of phe-
ochromocytoma or paraganglioma. DNA analysis was carried out for RET (exons 10, 11, 13, and 16), SDHB, SDHD, and VHL genes.
Techniques used for the analysis were direct sequence analysis, MSSCP, and RFLP.
Results: Germinal mutations were found in 16 patients (26,7%). Most frequent were mutations in RET proto-oncogene, followed by VHL
gene, one mutation in SDHB, and one in SDHD genes. A comparison of some of the clinical features of both groups (with and without
mutation) showed statistically significant differences.
Conclusions: The results of our study show that genetic predisposition is frequent in chromaffin tissue tumours, which indicates that
DNA analysis is necessary in every case, also because of possible atypical clinical presentation.
(Pol J Endocrinol 2010; 61 (1): 43–48)
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Streszczenie
Wstęp: Guzy chromochłonne i nerwiaki przyzwojowe wywodzą się z komórek grzebienia nerwowego i zlokalizowane są głównie
w rdzeniu nadnerczy oraz w zwojach autonomicznych współczulnych i przywspółczulnych. Mogą one (25%) stanowić składnik zespo-
łów wielogruczołowych, takich jak zespół MEN2, zespół von Hippela-Lindaua, zespół mnogich guzów chromochłonnych i nerwiaków
przyzwojowych (PPS, pheochromocytoma/paraganglinoma syndrome), a także nerwiakowłókniakowatości typu 1 czy zespołu Sturge-Webera.
Nie zawsze obraz kliniczny pozwala jednoznacznie określić rodzaj zespołu, dlatego badanie DNA może być pomocne w ustaleniu rozpo-
znania. Celem pracy była ocena częstości występowania dziedzicznie uwarunkowanych guzów chromochłonnych i przyzwojaków
u zgłaszanych jako pierwszy objaw.
Materiał i metody: Przeanalizowano DNA pochodzące od 60 chorych leczonych i diagnozowanych w Centrum Onkologii z powodu
guza chromochłonnego i nerwiaków przyzwojowych. Przeprowadzono analizę DNA w zakresie następujących genów: RET (eksony 10,
11, 13 i 16), SDHB, SDHD i VHL. Wykorzystywano sekwencjonowanie DNA, analizę MSSCP oraz analizę restrykcyjną.
Wyniki: Mutacje germinalne znaleziono u 16 chorych (26,7%). Najczęstsze były mutacje w genie RET, następnie w genie VHL oraz po
jednej mutacji w genach SDHB i SDHD. Analiza danych klinicznych chorych będących nosicielami mutacji wykazała znamienne staty-
stycznie różnice w porównaniu z grupą chorych z guzami sporadycznymi.
Wnioski: Przeprowadzone badania wskazują na częsty udział predyspozycji dziedzicznej w wystąpieniu guzów chromochłonnych, co
wskazuje na konieczność wykonywania badania DNA w każdym przypadku, także ze względu na możliwość nietypowego przebiegu
klinicznego, zwłaszcza w grupie chorych w wieku 20–40 lat. (Endokrynol Pol 2010; 61 (1): 43–48)
Słowa kluczowe: guz chromochłonny, nerwiak przyzwojowy, SDHB, SDHD, VHL, RET, analiza DNA
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Pheochromocytomas and other paragangliomas are
derived from neural crest cells, which eventually diffe-
rentiate into adrenal medulla and autonomic nervous
system paraganglia. Depending on the localization and
the ability of secretion and metabolisation of catecholami-
nes, they are called pheochromocytomas or paraganglio-
mas, and can be sympathetic or parasympathetic [1, 2].
Until recently, all secreting tumours, regardless of
localization, were called pheochromocytomas, i.e. tu-
mours derived from adrenal medulla, as well as sym-
pathetic paragangliomas, usually located in the retro-
peritoneal space. The name “paraganglioma” was used
only for non-secreting parasympathetic paragangliomas
usually located in mediastinum or in the region of bi-
furcation of the jugular artery (tumours of glomus ju-
gulare — chemodectomas) and the skull base. Curren-
tly the name “pheochromocytoma” is used only for tu-
mours of the adrenal medulla; other tumours are refer-
red to as paragangliomas.
The majority of these tumours are benign. The only
criterion for diagnosing malignancy is the presence of
metastases in the organs which normally lack the chro-
maffin cells [3, 4].
Pheochromocytomas often develop because of in-
herited syndromes like MEN2 (multiple endocrine neo-
plasia type 2), VHL (von Hippel-Lindau), or NF1 (neu-
rofibromatosis 1). In the past it was believed that these
tumours were inherited only in 10% of cases; at pre-
sent it is known that they have familial origin in about
25% of apparently sporadic tumours [5, 6]. These syn-
dromes are caused by germinal mutations of the predi-
sposing genes: RET proto-oncogene, VHL, NF-1 genes,
and three genes encoding subunits of succinyl dehy-
drogenase: SDHB, SDHD, and SDHC.
The role of these last genes in the development of
chromaffin tissue tumours was discovered only in 2002
[7]. Succinyl dehydrogenase is an enzyme playing a role
in cellular respiration as a component of both the tri-
carboxylic acid cycle and the respiratory chain. Muta-
tions in these genes are the cause of pheochromocyto-
ma/paraganglioma syndrome (PPS), traditionally called
PGL syndrome. In this syndrome, multiple tumours are
common: SDHD mutations connected mainly with be-
nign tumours of the head and neck region [8, 9], SDHB
mutations more often causing hormonally active and
malignant lesions. SDHC mutations are very rare and
mainly cause paragangliomas.
MEN2 syndromes are caused by mutations in RET
proto-oncogene activating the transmembrane protein
tyrosine kinase. In these syndromes, the main compo-
nent is medullary thyroid cancer. Pheochromocytomas
are present in about 50% of cases, in most cases benign,
often bilateral. In less than 20% of patients, hyperpara-
thyroidism can be present. In MEN2B syndrome, apart
from medullary thyroid cancer patients, the typical ha-
bitus presents thin posture, long, thin limbs, big lips,
and mucosal neuromas. Due to transmural neural ple-
xus hypertrophy, symptoms of megacolon may occur
[8, 9, 11].
Von Hippel-Lindau (VHL) syndrome symptoms can
vary and include haemangioblastomas of the central
nervous system (CNS) and retina, clear cell renal carci-
noma and pheochromocytoma, and other symptoms
with less specificity, such as cysts of the pancreas, kid-
neys, epididymis, and broad ligament of the uterus.
Pheochromocytomas appear in 10–26% of cases, main-
ly located in the adrenal medulla, in most cases as be-
nign tumours. VHL syndrome is caused by inactivating
mutations of the VHL gene involved in angiogenesis
and regulating hypoxia [12, 13].
NF1 syndrome is quite frequent and is characteri-
zed by neurofibromas, café au lait spots, iris lesions
(Lisch nodules), and adrenal pheochromocytomas.
The latter are a rare component of the syndrome (0.1–
–5.7%) and are more frequent in patients with hyper-
tension [14–16].
The presented study is part of a multicenter project
concerned with the genetic predisposition to chromaf-
fin tissue tumours.
The aim of the study is to evaluate the frequency of
hereditary chromaffin tissue tumours in patients with
apparently sporadic pheochromocytomas from the
material of the Institute of our department and coope-
rating centres.
Material and methods
The subjects of the study were 60 patients with diagno-
sis of pheochromocytoma or paraganglioma referred for
genetic evaluation. The diagnosis was made based on
histopathology in 55 patients. The remaining five pa-
tients were not operated on, and the diagnosis was ba-
sed on typical clinical manifestation, biochemical abnor-
malities, and radiological or scintigraphic imaging. Phe-
ochromocytoma was diagnosed in 52 (77.4%) and pa-
raganglioma in 9 (15%) patients; among them was one
case of chemodectoma. One patient had both pheochro-
mocytoma and paraganglioma (Table I).
Among the patients with pheochromocytoma,
41 had benign tumours (78.8%) and malignant lesion
was present in 11 (20.7%). Malignancy was diagnosed
when distant metastases were discovered. Sites of me-
tastases were bones (4 patients), liver (5 patients), lungs
(5 patients), and lymph nodes of the thoracic or abdo-
minal cavity (5 patients). One person had multiple me-
tastases in the left kidney.
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Mean age of diagnosis was 35.6 years (11–65 years).
Genetic diagnosis was carried out for MEN2, VHL,
and PPS syndromes. This was based on the clinical exa-
mination and DNA analysis.
For the analysis, a blood sample was taken and DNA
of the leukocytes was isolated with the use of the pro-
teinase K and SDS. Then was extracted with NaCl and
ethyl alcohol and dissolved in sterile deionised water.
Isolated DNA was then amplified with the use of poly-
merase chain reaction (PCR). The amplification was car-
ried out for all exons of SDHB, SDHD, and VHL genes,
and exons 10, 11, 14, and 16 of RET proto-oncogene
under conditions specific for each exon. The reaction
was held in a mixture containing dNTPS, F, and R pri-
mers, MgCl2, buffer, water, and DNA polymerase Hot-
StartTaq. The reaction consisted of 35 cycles of diffe-
rent temperature conditions. The result of the reaction
was then visualized on agarose gel with the use of ethi-
dine bromide.
For the SDHB and SDHD genes, multi-temperatu-
re, single-strand conformation (MSSCP) analysis on the
polyacrylamide gel was then performed with the use
of a DNA Pointer System (Kucharczyk TE) and the re-
sults visualized with the use of the silver stain method.
In the case of detection of DNA conformation change,
sequence analysis was performed. For the exons of VHL
and RET genes, sequence analysis was carried out as
well (Applied Biosystem/Hitachi).
Results
Patients with germline mutations found in analyzed
genes are characterized in Table II and the frequency
of the mutations in Table III.
Germinal mutations were found in 16 out of 60 pa-
tients, which is 26.7%. Most common were mutations
in the proto-oncogene RET (n = 11; 18.3%). Next were
the VHL mutations (n = 3; 7.7%), and the mutations in
SDHB and SDHD genes were found in two patients
(3.4%).
In the group of patients with pheochromocytoma,
mutations were found in 14 cases (26.9%), in benign
tumours in 12 cases (29.3%), and malignant in 2 cases
(18.2%). These were mutations in RET proto-oncogene
(codons 634 and 791) and the VHL gene.
In the group of patients with paragangliomas, mu-
tations were found in two cases (25%): in one patient
with benign chemodectoma (mutation in SDHD gene)
and one patient with malignant paraganglioma of the
bladder with metastases in the iliac artery lymph nodes
(SDHB mutation).
Among the RET mutations, most common was the
mutation in exon 11 codon 634, present in six cases. All
of these patients underwent full diagnostic procedu-
res, and medullary thyroid cancer was eventually dia-
gnosed in all cases. Two of them also had primary hy-
perparathyreoidismus. The pheochromocytomas in the-
se patients were all secreting and localized in the adre-
nal medulla. Three patients had unilateral lesion, two
developed second tumours and required a second ad-
renalectomy in the course of follow-up, and one patient
had two tumours at presentation, which were then re-
moved during one operation.
Among five patients with codon 791 mutation, thy-
roid nodules were diagnosed only in two of them but
repeated FNAB revealed benign lesions. In all of these
patients, repeated pentagastrin stimulation tests were
within the normal range, thus no indications for pro-
phylactic thyroidectomy were stated. Three of these
patients had single adrenal tumours which were remo-
ved. In one patient, diagnosed because of unstable hy-
pertension at the age of 14 years, a small paraganglio-
ma of the retroperitoneal space was found. Another
patient was operated on twice because of the recurren-
ce and also underwent 131I-MIBG treatment because of
metastases in the abdominal lymph nodes.
In the VHL gene we found three different mutations:
in codon 64 associated with bilateral pheochromocyto-
mas; in codon 112 in a patient with malignant pheochro-
mocytoma with abdominal lymph node and bone me-
tastases; in codon 125 in a patient with bilateral phe-
ochromocytomas, clear cell renal cancer, and blindness
of the left eye because of retinal haemangioblastoma
history — in the course of later diagnostic procedures,
cerebellar haemangioblastoma was also found.
A mutation was found in exon 6 of SDHB gene in
a patient with malignant paraganglioma of the bladder
with concomitant regional lymph node metastases. In
SDHD gene, a mutation was found in exon 1 in a pa-
tient with benign chemodectoma, who completely re-
covered after operation.
The average age of diagnosis was 30 years ± 16 years
(11–68 years). Nine of those patients (50%) were under
20 years old at diagnosis, 5 (27.8%) were less than
40 years old, and only 22.2% of this group (n = 4) were
older than 40 years. When compared to the group of
patients in whom familial predisposition was excluded
Table I. Description of the studied group
Tabela I. Opis badanej grupy




*One case of pheochromocytoma and paraganglioma
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because of DNA analysis, the age of diagnosis was hi-
gher — 41 years ± 13.7 years (12–72 years). In the age
range less than 20 years old only three out of 42 spora-
dic patients (7%) had undergone operation. This diffe-
rence was statistically significant (p = 0.003). Thirteen
(31%) patients were diagnosed in the age of 20–40 years,
and the majority were operated on during the age ran-
ge over 40 years (n = 26; 62%). This difference is not
statistically significant (p = 0.12). Only 1/3 of these pa-
tients (n = 6) had single tumours: adrenal (n = 4) or
extra-adrenal (n = 2). In eight out of the 18 inherited
cases, additional lesions appeared in the course of the
disease, whereas in the group of sporadic tumours,
multiple lesions were present only in 12%. This diffe-
rence was also statistically significant (p = 0.03).
The majority (n = 12; 66%) had multiple or mali-
gnant lesions. In comparison with the group without
familial predisposition, the age of diagnosis was higher
— 41 years ± 13.7 years (12–72 years). In the age range
less than 20, only three out of 42 patients (7%) had
undergone the operation, 13 (31%) in the age of 20–
–40 years, and the majority in the age over 40 (n = 26;
62%). In this group, complete remission was achieved
in 30 (72%) patients. The difference between the num-
ber of multiple and malignant lesions in these two gro-
ups is also statistically significant (p = 0.03).
Discussion
We analyzed the genetic cause of pheochromocytomas
and paragangliomas in patients with apparently spora-
dic tumours. The DNA analysis was carried out for four
genes: RET, VHL, SDHB, and D [17]. The third SDH gene
— SDHC — was not analyzed at this point because its
mutations are extremely rare — 4% in paragangliomas
Table III. Frequency of mutations/inherited syndromes
Tabela III. Częstość mutacji/zespołów dziedzicznych
Gene Localization Number Frequency
RET codon 634 6 10%
codon 791 5 8.3%
Total 11 18.3%
vHL codon 64 1 2.6%
codon 112 1 2.6%
codon 125 1 2.6%
Total 3 7.7%
SDHB-D N 721 G-A 1 2.6%





Table II. Clinical characteristic of the studied group
Tabela II. Charakterystyka kliniczna badanej grupy
Lp Initials AOD Dgn Localization Single/multiple Malignant Syndrome Mutation
1 MB 19 Pgl Bladder Multiple Yes PGL SDHB
2 PG 39 Pheo Right adrenal gland Single No MEN2A RET 791
3 MJ 28 Pheo Both adrenal glands Multiple No MEN2A RET 634
4 BJ 16 Pheo Both adrenal glands Multiple No – VHL 64
5 JJ 28 Pheo Both adrenal glands Multiple No MEN2A RET 634
6 BK 20 Pheo Left adrenal gland Single Yes MEN2A RET 791
7 MK 14 Pgl Both adrenal glands Multiple No – SDHD 196
8 MK 20 Pheo Both adrenal glands Multiple No MEN2A RET 634
9 JL 14 Pgl Retroperitoneum Single No MEN2A RET 791
10 AL 18 Pheo Both adrenal glands Multiple No – VHL 125
11 JM 53 Pheo Both adrenal glands Multiple No MEN2A RET 634
12 WP 31 Pheo Both adrenal glands Multiple No MEN2A RET 634
13 MS 11 Pheo Right adrenal gland Single Yes – VHL 112
14 RT 68 Pheo Left adrenal gland Single No MEN2A RET 791
15 IW 23 Pheo Left adrenal gland Single No MEN2A RET 791
16 HŻ 50 Pheo Right adrenal gland Single No MEN2A RET 634
17 BL 49 Pheo Left adrenal gland Single No NF1 Not analyzed
18 GJ 11 Pgl Retroperitoneum Multiple Yes Sturge-Weber Not analyzed
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only. NF1 diagnosis was based on clinical symptoms
only [22].
Based on the DNA analysis, hereditary origin of
pheochromocytomas was found in 16 cases (26.7%).
Additionally, in one patient we found clinical features
pointing to NF 1 syndrome and in another, family hi-
story pointed to Sturge-Weber syndrome, so these pa-
tients could also be treated as hereditary cases. With
the addition of these two cases, the prevalence of fami-
lial tumours rises to 30%. Our findings are similar to
these of a larger multicentre international study in
which pheochromocytomas were found out to be in-
herited in 25% [6] of cases, higher than in other surveys.
The presented material consists not only of the more
difficult cases transferred for further diagnosis, but also
of patients with unequivocal diagnosis of hereditary
tumours transferred for further follow-up. This expla-
ins the higher contribution of hereditary pheochromo-
cytomas.
In our material, RET proto-oncogene mutations were
most frequent. They were observed in 11 patients, 18.3%
of all cases and 68% of all found mutations. Mutations
in codon 634 were found in six and in codon 791 in five
cases. In the patients with codon 634 mutations [21],
further procedures led to the diagnosis of medullary
thyroid cancer, thus they could be regarded as missed
clinically apparent MEN2 cases. Nevertheless, in the
situation of high frequency of thyroid goiter in Poland
and limited access to calcitonin estimation, referral to
DNA diagnosis was the deciding step in the proper dia-
gnosis and speeded up the detection of medullary thy-
roid cancer. The pheochromocytomas in these cases
were all located in the adrenal glands, were benign, and
in many cases bilateral, which is a typical feature of
MEN2A syndrome according to the literature [15].
The clinical course of the disease in patients with
codon 791 mutation was different. None of these pa-
tients developed thyroid cancer, one of the pheochro-
mocytomas was malignant, and there was one case of
paraganglioma.
Management of the carriers of these two mutations
is also different. Most recommendations also advise
prophylactic thyroidectomy in patients with codon 791
mutation. However, they concern children. In most of
our patients, DNA analysis had already been perfor-
med in adulthood and further diagnosis showed no
cause for suspicion of MTC. It can thus be presumed
that the transforming potential of the mutation is weak,
especially when no C cell hyperplasia is present, which
was proven by negative pentagastrin stimulation test
in all of our patients. In addition, the family history was
negative in all cases. In this situation, we decided not to
perform prophylactic thyroidectomy [19].
Mutations in VHL gene were associated with adre-
nal tumours and relatively young age of diagnosis. The
risk of the malignancy is known to be very low [6, 15],
although in our studied group we describe one patient
with an obviously malignant, metastatic tumour.
Mutations in SDHB and SDHD genes were associa-
ted with the young age of onset. The only carrier of
SDHD mutation found in our group had benign che-
modectoma with complete remission after surgery. This
mutation is the most common mutation (“hot spot”) in
the central European population (Poland/Germany)
[20]. A mutation in the SDHB gene was observed in one
patient with extra-adrenal paraganglioma with meta-
stases of the lymph nodes. These findings are also in
accordance with the literature data [10].
It is still not fully understood why the course of di-
sease is different in the carriers of SDHB mutations from
in those with SDHD mutations. Baysal suggests that
there is a different pattern of expression of the tumours
located above and below the diaphragm [7], whereas
Jimenez points out the fact that SDHB encodes the sub-
unit with full catalytic ability whereas SDHD and SDHC
encode subunits harbouring catalytic subunits to the
mitochondrial membrane [15].
It is believed that tumours appearing at a youn-
ger age are caused by hereditary syndrome [1, 2, 21].
When the criterion of a minimum of 20 years of age
was taken into consideration, the difference was si-
gnificant. We think that in the age group 20–40 years
of age, DNA analysis, especially when a single tumo-
ur is present, can be most helpful in diagnosing in-
herited syndromes.
Inherited tumours were strongly associated with
multiple disease foci and were statistically significant.
Malignant tumours were present in four mutation car-
riers (28%) and in nine patients with sporadic tumours
(21%). Thus, in contrast to some other publications [23,
24] we did not observe a strong correlation between
malignancy and predisposing gene mutation related
tumours, which is perhaps due to the low number of
cases or to the bias related to the reference of more
malignant cases in the truly sporadic group as well.
Conclusions
Our results point out that DNA analysis is necessary in
every case of apparently sporadic pheochromocytoma
and paraganglioma in order to diagnose hereditary syn-
dromes that may have an untypical course.
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